Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

230
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
230
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

427
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
427
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.5K
Chronic Obstructive Pulmonary Disease01:22

Chronic Obstructive Pulmonary Disease

1.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.2K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
2.7K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

177
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
177

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cutaneous <i>Staphylococcus aureus</i> Infections in Renal Edema Across Kidney Disease and the Intensive Care Unit: Pathophysiological Mechanisms, Clinical Implications, and Therapeutic Challenges.

International journal of molecular sciences·2026
Same author

Combined Atrial Functional Mitral and Tricuspid Regurgitation in Atrial Fibrillation: Prevalence, Associated Factors, and Three-Dimensional Valve Remodeling.

Journal of clinical medicine·2026
Same author

Oxidative Stress Biomarkers and Systemic Inflammatory Indices in Metabolic Dysfunction-Associated Steatotic Liver Disease with Type 2 Diabetes Mellitus: A Comparative and Longitudinal Analysis.

International journal of molecular sciences·2026
Same author

Seeing beyond muscle loss: why ultrasound matters in sarcopenia?

Medical ultrasonography·2026
Same author

Diaphragmatic Muscle Thickness: A Complementary Tool in Assessing Lung Involvement in Patients with Systemic Sclerosis.

Medical sciences (Basel, Switzerland)·2026
Same author

Spontaneous Resolution of a Bilateral Barrow Type D Indirect Carotid-Cavernous Fistula: A Rare Case Report and Literature Review.

Diagnostics (Basel, Switzerland)·2026

Related Experiment Video

Updated: Jun 3, 2025

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome
04:49

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome

Published on: July 5, 2024

912

COPA Syndrome-From Pathogenesis to Treatment.

Vlad Padureanu1, Mircea-Cătălin Forțofoiu1, Ionut Donoiu2

  • 1Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.

Diagnostics (Basel, Switzerland)
|January 8, 2025
PubMed
Summary

Coatomer subunit α (COPA) syndrome causes early lung disease and immune issues. JAK inhibitor therapy shows promise for managing COPA syndrome, offering hope for improved patient life expectancy.

Keywords:
COPA syndromearthritisdiffuse alveolar hemorrhagingimmune dysregulationinterstitial lung disease

More Related Videos

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing &#946;-galactosidase
08:48

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase

Published on: November 5, 2021

3.2K
Direct Re-implantation of Left Coronary Artery into the Aorta in Adults with Anomalous Origin of Left Coronary Artery from the Pulmonary Artery ALCAPA
13:10

Direct Re-implantation of Left Coronary Artery into the Aorta in Adults with Anomalous Origin of Left Coronary Artery from the Pulmonary Artery ALCAPA

Published on: April 24, 2017

18.5K

Related Experiment Videos

Last Updated: Jun 3, 2025

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome
04:49

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome

Published on: July 5, 2024

912
In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing &#946;-galactosidase
08:48

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase

Published on: November 5, 2021

3.2K
Direct Re-implantation of Left Coronary Artery into the Aorta in Adults with Anomalous Origin of Left Coronary Artery from the Pulmonary Artery ALCAPA
13:10

Direct Re-implantation of Left Coronary Artery into the Aorta in Adults with Anomalous Origin of Left Coronary Artery from the Pulmonary Artery ALCAPA

Published on: April 24, 2017

18.5K

Area of Science:

  • Immunology
  • Genetics
  • Pulmonology

Background:

  • Coatomer subunit α (COPA) syndrome is an autosomal dominant immune dysregulation disease.
  • It presents with early-onset lung disease (diffuse alveolar hemorrhage or interstitial lung disease), arthritis, and glomerulonephritis.
  • Patients often have high-titer autoantibodies, mimicking other autoimmune conditions.

Purpose of the Study:

  • To review the current understanding of COPA syndrome.
  • To evaluate the effectiveness of immunosuppressive medications and explore novel therapeutic options.
  • To highlight the challenges in managing long-term lung disease progression in COPA syndrome patients.

Main Methods:

  • Literature review of mendelian autoimmune diseases.
  • Analysis of clinical data on COPA syndrome patients.
  • Evaluation of therapeutic strategies including immunosuppressants and JAK inhibitors.

Main Results:

  • Immunosuppressive drugs show efficacy in controlling arthritis associated with COPA syndrome.
  • Long-term data on lung disease control in COPA syndrome remains limited.
  • JAK inhibitor therapy emerges as a promising therapeutic approach for COPA syndrome.

Conclusions:

  • COPA syndrome requires comprehensive management strategies due to its complex presentation.
  • Effective control of lung disease progression is critical for improving life expectancy in COPA patients.
  • JAK inhibitors represent a potential breakthrough in treating COPA syndrome, warranting further investigation.